Fundraising FoxHEALTHCARE ROYALTY PARTNERS — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Karyopharm Therapeuticskaryopharm.comin𝕏Dec 2022
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.
BiotechHealthtechNewton, US
Stuart Poulton(Executive Officer)inMichael Mano(Executive Officer)inReshma Rangwala(Executive Officer)inRichard Paulson(CEO)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in
Co-investorsAvoro Capital AdvisorsForesite CapitalRA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.